Predicting cancer versus autism risk in PTEN patients
In a new study, a team of researchers led by Charis Eng, M.D., Ph.D., Chair of Cleveland Clinic’s Genomic Medicine Institute, identified a metabolite that may predict whether individuals with PTEN mutations will develop cancer or autism spectrum disorder (ASD). Germline mutations of the tumour suppressor gene PTEN are associated with a spectrum of rare […]
